N1VO34:BVMF
Novo Nordisk Bdr
R$24.51
0.00%
(0.00) 1D
Oct 19, 5:06:00 PM GMT-3 · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for N1VO34...
Open
R$24.40
High
R$24.51
Low
R$24.24
Mkt. cap
130.72B
Avg. vol.
34.08K
Volume
4.34K
52-wk high
R$42.43
52-wk low
R$22.90
Shares outstanding
3.39B
No. of employees
67K
Open
R$24.40
High
R$24.51
Low
R$24.24
Mkt. cap
130.72B
Avg. vol.
34.08K
Volume
4.34K
52-wk high
R$42.43
52-wk low
R$22.90
Shares outstanding
3.39B
No. of employees
67K
News stories
From web sources and news partners
Foreign Policy Journal
·
44 minutes ago
Novo Nordisk A/S (NYSE: NVO) Holds Zacks Rank #3 As Earnings Estimates Slide And Valuation Looks Attractive
Yahoo Finance
·
3 hours ago
Novo Nordisk (NVO) Stock Sinks As Market Gains: Here's Why
The Motley Fool
·
8 hours ago
Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market
MedWatch
·
11 hours ago
Novo Nordisk management draws criticism for not buying shares
Profile
Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily obesity and diabetes medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark, and it became the highest valued company in Europe. Wikipedia
About Novo Nordisk Bdr
CEOMike Doustdar
Employees66.7K
Founded1923
HeadquartersBagsværd, Capital Region of Denmark, Denmark
SectorPharmaceutical industry
Websitenovonordisk.com